Alecensa Approved for Lung Cancer Tied to Gene Mutation

FRIDAY, Dec. 11, 2015 — Alecensa (alectinib) has been approved by the U.S. Food and Drug administration to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, the agency said Friday in a news release. This type of cancer…
Source: Topamax